4,N-Dimethylbicyclo<2.2.2>octan-1-amine | 31818-25-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4,N-Dimethylbicyclo<2.2.2>octan-1-amine
• 英文别名: N,4-Dimethylbicyclo<2.2.2>octan-1-amin；N,4-Dimethylbicyclo[2.2.2]octan-1-amin；N,4-Dimethylbicyclo[2.2.2]octan-1-amine
• CAS: 31818-25-4
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: CEGQNLSCPJZDPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  松油烯 在 platinum(IV) oxide 、 vanadia lithium aluminium tetrahydride 、 sodium azide 、 硫酸 、 氢气 、 硝酸 作用下， 以 甲醇 、 乙醚 、 氯仿 、 溶剂黄146 、 苯 为溶剂， 生成 4,N-Dimethylbicyclo<2.2.2>octan-1-amine
  参考文献：
  名称：

  抗病毒药。I.双环[2.2.2]辛烷和-辛-2-烯胺。

  摘要：

  DOI：

  10.1021/jm00296a021

文献信息

• SUBSTITUTED ARYL COMPOUND
  申请人：Simcere Pharmaceutical Co., Ltd.

  公开号：EP4108663A1

  公开（公告）日：2022-12-28

  The present application describes a substituted aryl compound used as an RAD51 inhibitor and a pharmaceutically acceptable salt thereof. The compound has the structure as represented by Formula (I) and has the substituents and structural features as described in the present application. Furthermore, the present application describes a pharmaceutical composition containing the compound as represented by Formula (I) or the pharmaceutically acceptable salt thereof, and the use of the compound as represented by Formula (I) or the pharmaceutically acceptable salt thereof and the pharmaceutical composition containing same in the preparation of a drug for preventing or treating RAD51 mediated diseases.

  本申请描述了一种用作 RAD51 抑制剂的取代芳基化合物及其药学上可接受的盐。该化合物具有式（I）所代表的结构，并具有本申请中所描述的取代基和结构特征。此外，本申请还描述了一种含有式（I）所代表的化合物或其药学上可接受的盐的药物组合物，以及式（I）所代表的化合物或其药学上可接受的盐和含有该化合物的药物组合物在制备预防或治疗RAD51介导的疾病的药物中的用途。
• ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS
  申请人：BUSATH David D.

  公开号：US20170128489A1

  公开（公告）日：2017-05-11

  Organo-transition metal complexes possess anti-viral inhibitory activity against influenza A, including the S3 IN mutant. The organo-transition metal complexes include a transition metal and at least one ligand based on the structure of an M2 proton channel blocker. Compounds and pharmaceutical compositions are useful for treating viruses such as influenza A.
• US7449447B2
  申请人：——

  公开号：US7449447B2

  公开（公告）日：2008-11-11
• [EN] NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS<br/>[FR] NOUVEAUX INHIBITEURS PEPTIDOMIMETIQUES DE LA SERINE PROTEASE NS3 DU VIRUS DE L'HEPATITE C
  申请人：SCHERING CORP

  公开号：WO2005021584A2

  公开（公告）日：2005-03-10

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers or racemates of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula (1): useful in the treatment or prevention or amelioration of one or more symptoms of hepatitis C.
• Antiviral agents. I. Bicyclo[2.2.2]octan- and -oct-2-enamines
  作者：Joel G. Whitney、W. A. Gregory、J. C. Kauer、J. R. Roland、Jack A. Snyder、R. E. Benson、E. C. Hermann

  DOI：10.1021/jm00296a021

  日期：1970.3